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OBJECTIVES The study investigated the relationship among creatine kinase (CK) elevations, clinical
characteristics and cardiac events across the whole spectrum of acute coronary syndromes
(ACS).
BACKGROUND Elevated serum levels of cardiac enzymes have been shown to be a major prognostic
determinant in acute myocardial ischemia. Yet prior to this report, the relation between
cardiac enzyme levels and other prognostic determinants across the entire spectrum of ACS
has not been explored by a large clinical study.
METHODS We evaluated the relation between the maximum CK ratio (CK level/upper limit of normal)
in the early hours following admission and cardiac events at six months in 11,725 patients
enrolled in a large trial of ACS.
RESULTS Patients with higher risk characteristics, such as older age, female gender, hypertension,
diabetes, prior coronary events or heart failure, more frequently presented without ST-
segment elevation on the electrocardiogram and tended to develop lesser enzyme elevations.
After adjusting for significant baseline predictors of cardiac events, a continuous correlation
was observed between the CK ratio and death (chi-square 63.04, p  0.0001) and
(re)infarction or death (chi-square 55.48, p  0.0001). This correlation was similar for
patients with and without ST-segment elevation. The adjusted incidence of cardiac events at
follow-up began to rise even for CK levels within the normal range, the steepest part of the
curve residing between one and three times the upper limit of normal. In patients with a CK
ratio of 1 to 2 compared with those within the normal range, the adjusted odds ratio for
death was 1.26 (95% confidence interval [CI] 0.98 to 1.63), and 1.59 (95% CI 1.38 to 1.90)
for (re)infarction and death. For all CK levels, the event rate was higher among patients
without ST-segment elevation.
CONCLUSIONS Although high-risk patients with ACS often develop lesser CK elevations, this study
demonstrated that even minor enzyme elevations appear to have important and independent
prognostic implications. (J Am Coll Cardiol 2002;39:22–9) © 2002 by the American
College of Cardiology
Elevated cardiac enzyme levels during an episode of acute
myocardial ischemia have been shown to imply a worse
prognosis (1). A number of experimental and clinical studies
have illustrated the relation between the amount of myo-
cardial damage estimated by serum levels of creatine kinase
(CK) and infarct size and the incidence and severity of heart
failure, ventricular arrhythmias, left ventricular dysfunction
and, ultimately, clinical outcomes (2–10). This model has
been particularly validated for patients with myocardial
infarction (MI) and ST-segment elevation. More recently,
the focus has shifted to the prognostic importance of
enzyme elevations in non–ST-segment elevation acute cor-
onary syndromes (ACS) (11). However, the prognostic
significance of CK levels in a large population of patients
encompassing the entire range of ACS, the relative impor-
tance of CK elevations in patients with or without ST-
segment elevation and the relation between CK levels and
other prognostically meaningful baseline characteristics have
not been investigated. The Global Use of Strategies to
Open Occluded Coronary Arteries (GUSTO)-IIb trial
offers a unique opportunity to explore these issues because it
is presently the only study to have enrolled the entire
spectrum of patients with ACS, including those with recent
or ongoing chest pain and electrocardiographic (ECG) signs
of acute myocardial ischemia (12).
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METHODS
Patient population. The GUSTO-IIb trial enrolled
12,142 patients with symptoms of cardiac ischemia at rest
within 12 h of admission and accompanying ECG signs of
acute ischemia defined as either transient or persistent
ST-segment elevation or depression (0.05 mV), or per-
sistent and definite T-wave inversion (0.1 mV) (12).
Patient enrollment was balanced to include two-thirds of
patients without ST-segment elevation and one-third of
patients with ST-segment elevation. All patients were
treated with antithrombotic therapy including aspirin and
either hirudin or heparin (for 48 to 72 h according to a
randomized, double-blind schedule), fibrinolytic therapy
when indicated and anti-ischemic drugs. Revascularization
procedures were discouraged for the first 48 to 72 h unless
there was evidence of recurrent ischemia.
CK measurements. Enzymes were measured according to
local hospital standards. During the pretrial phase, a specific
form was sent to each of the participating centers in which
the normal laboratory ranges for CK and creatine kinase-
myocardial band (CK-MB) had to be reported, and the
form was returned to the data coordinating center. The CK
and, if available, CK-MB levels were determined at admis-
sion, 6 to 8 h after admission and 12 to 16 h after admission
so as to reflect the enzyme elevation consequence of the
event leading to enrollment. Overall, 98% of the patients
had CK levels measured; CK-MB values were available for
only 56% of patients. Therefore, only CK values were used
in this analysis.
End points. The primary end point of the GUSTO-IIb
trial was the composite of death and (re)MI at 30 days,
whereas the incidences of death and (re)MI at six months
were secondary end points. However, the present study
focused on mortality and the combined end point of death
and (re)MI at six-month follow-up. Figure 1 shows the
distribution of patients according to the availability of CK
measurements and end point data for this study.
Patient’s vital status was derived from the 30-day and
six-month follow-up forms completed by the investigators
after a medical examination, a patient’s self-administered
questionnaire or by telephone interview. The (re)MI was
defined based on either cardiac enzyme or ECG evidence.
Enzyme evidence was defined as a (re)elevation of CK-MB
to above the upper limit of normal if the prior level was in
the normal range, or 50% above the prior level if the prior
level was above normal range. If CK-MB was not available,
then the total CK elevation must have been greater than two
times above the upper limit of normal and increased by at
least 25% or 200 U/ml over the previous value. The ECG
evidence of recurrent MI was defined as new, significant Q
Abbreviations and Acronyms
ACS  acute coronary syndromes
CK  creatine kinase
CK-MB  creatine kinase-myocardial band
ECG  electrocardiogram/electrocardiographic
GUSTO-IIb  Global Use of Strategies to Open
Occluded Coronary Arteries-IIb trial
MI  myocardial infarction
PTCA  percutaneous transluminal coronary
angioplasty
Figure 1. Distribution of patients for each end point. CK  creatine kinase; MI  myocardial infarction.
23JACC Vol. 39, No. 1, 2002 Savonitto et al.
January 2, 2002:22–9 CK Elevations and Prognosis in ACS
waves in at least two leads and discrete from the enrollment
MI. All of the events were adjudicated by the clinical events
committee at the coordinating center.
The events occurring during the initial hospital stay were
adjudicated following a review of all source documents,
whereas those occurring after hospital discharge were de-
rived from the 30-day and six-month follow-up forms
completed by the investigators. Because the present study
examined the relation between the maximal CK level
recorded during the episode leading to the index hospital
admission and the incidences of subsequent events, the 95
patients who died within 16 h from admission were not
included in the analysis, and MIs that occurred during the
first 16 h of the index hospital admission were not consid-
ered as end points.
Statistical analysis. The absolute CK values reported in
each patient’s case record form were computer-transformed
to CK ratios according to the following formula: CK ratio
CK level divided by the upper limit of normal in the local
laboratory. As a continuous measure, the maximum CK
ratio among the three measurements taken at admission, 6
to 8 h after admission and 12 to 16 h after admission was
used. As a categorical measure, the maximum CK ratio was
broken down into the following categories: 0 to 1 time, 1
to 2 times, 2 to 5 times and 5 times the upper limit of
normal. The relation between these categories and baseline
factors was described by using medians with 25th and 75th
percentiles for continuous measures and percentages for
categorical measures. Percentages of patients with and
frequencies of events within each of these four categories of
maximum CK ratio were also used in illustrating the
association of increasing CK levels with death, (re)MI and
death or (re)MI.
To explore the relationship of CK ratio with cardiac
events within six months, logistic regression analysis was
used. The CK ratio was considered both as a continuous and
as a categorical measure. For both outcomes of death and
death or (re)MI in six months, the continuous measure of
the maximum CK ratio was modeled using a three-knot
cubic spline transformation. Graphs of the average pre-
dicted probability of the outcome by the maximum CK ratio
were used to demonstrate the shape of the effect. By using
the patient’s baseline characteristics in the models, predicted
probabilities were calculated for each patient for values of
CK ratio from 0 to 20. The average predicted value for each
CK ratio was then plotted. Odds ratios (ORs) with 95%
confidence intervals were used to demonstrate the effect of
maximum CK ratio as a categorical measure on outcome.
Interactions between maximum CK ratio and strata (ST-
segment elevation, non–ST-segment elevation) were ex-
plored for both outcomes for maximum CK ratio as a
continuous and categorical measure.
To provide an adjusted effect of maximum CK ratio on
outcome, baseline characteristics that were determined to be
predictive of 30-day death and 30-day death and (re)MI in
the GUSTO-IIb model (13) were used as adjustment
factors in the models of six-month outcomes. The variables
found to be predictive of death were age, heart rate, Killip
class, systolic and diastolic blood pressure, previous MI,
gender, peripheral vascular disease, hypertension, height,
chronic renal insufficiency, hyperlipidemia, smoking status,
family history of coronary disease, previous percutaneous
transluminal coronary angioplasty (PTCA), weight and
diabetes. The variables found to be predictive of death or
(re)MI were age, heart rate, Killip class, systolic and
diastolic blood pressure, previous MI, gender (and interac-
tion with strata), peripheral vascular disease, hypertension,
height, chronic renal insufficiency (and interaction with
strata), ECG strata and previous angina. These variables,
excluding those highly nonsignificant in predicting events
within six months (namely, smoking status and family
history of coronary disease did not predict death, and ECG
strata did not predict death or [re]MI), were used to provide
an adjusted effect of maximum CK ratio on six-month
mortality and death or (re)MI.
RESULTS
CK levels and baseline characteristics. Of the 11,725
patients with recorded CK ratio who survived the first 16 h
after admission and had six-month survival data, 4,814
(41%) had a maximum CK ratio of 1; 1,546 (13%) 1 to
2; 1,985 (17%) 2 to 5; and 3,380 (29%) 5. As shown in
Figure 2, the majority of patients in the higher CK
categories were in the ST-segment elevation cohort, and
patients in the normal or lower CK categories were in the
non–ST-segment elevation cohort. Compared with the
ST-segment elevation group on hospital admission, patients
without ST-segment elevation were older, more frequently
women, and had a higher prevalence of risk factors for
coronary disease and of previous coronary events (Table 1).
However, the distribution of baseline characteristics among
levels of CK ratio was similar in the ST-segment elevation
and non–ST-segment elevation strata. Patients with normal
Figure 2. Percentages of patients with creatine kinase (CK) ratios of 0 to
1, 1 to 2, 2 to 5 and 5 within 16 h from hospital admission in the
total study population and in the cohorts with ST-segment elevation and
non–ST-segment elevation on the admission electrocardiogram.
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or minimally elevated enzyme levels tended to be older.
Patients with lower enzyme levels also tended to have higher
risk characteristics such as hypertension, diabetes, previous
MIs, angina, congestive heart failure, PTCA or bypass
operations.
CK levels and cardiac events. The incidence of cardiac
events at six months is shown in Table 2, and the total
patient population examined (11,725) included those who
survived the first 16 h after hospital admission and provided
follow-up data. In this population, an increase in CK ratio
was associated with an increase in mortality in the highest
CK category, and the incidence of death or (re)MI appeared
to increase for all CK values above normal levels (Table 2).
In patients without ST-segment elevation, a higher mortal-
ity was observed most strongly with a CK ratio of 5,
whereas the incidence of (re)MI increased with even min-
Table 1. Baseline Characteristics by Peak CK Ratio
Variable* Strata
CK Ratio 0–1
(n  4,911)
CK Ratio >1–2
(n  1,570)
CK Ratio >2–5
(n  2,005)
CK Ratio >5
(n  3,414)
Age (yrs) Total population 66 (57, 73) 65 (55, 72) 65 (56, 72) 63 (53, 71)
Median (25th, 75th percentiles) ST-elevation 65 (55, 72) 64 (54, 71) 65 (54, 71) 62 (52, 70)
Non–ST-elevation 66 (57, 73) 65 (55, 73) 65 (57, 73) 64 (55, 73)
Gender (% Female) Total population 36 30 26 23
ST-elevation 28 27 26 22
Non–ST-elevation 38 31 26 26
Hypertension Total population 49 48 45 39
ST-elevation 44 46 42 37
Non–ST-elevation 49 48 46 42
Diabetes Total population 19 19 16 16
ST-elevation 19 19 14 16
Non–ST-elevation 19 20 18 16
Hypercholesterolemia Total population 41 42 39 36
ST-elevation 37 40 37 35
Non–ST-elevation 42 43 40 37
Previous MI Total population 34 31 25 15
ST-elevation 30 25 19 12
Non–ST-elevation 34 32 29 23
Previous angina Total population 81 72 64 46
ST-elevation 67 57 50 41
Non–ST-elevation 83 76 71 57
Prior CHF Total population 8 5 4 3
ST-elevation 7 3 2 2
Non–ST-elevation 8 6 5 4
Prior PTCA Total population 13 9 7 4
ST-elevation 10 9 7 4
Non–ST-elevation 13 9 6 5
Prior CABG Total population 14 10 9 4
ST-elevation 10 8 6 3
Non–ST-elevation 14 11 11 6
*Unless noted, all variables are taken from a percentage of patients.
CABG  coronary artery bypass grafting; CHF  congestive heart failure; CK  creatine kinase; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty.
Table 2. Mortality, (Re)MI and Death or Re(MI) at Six Months According to Peak CK Ratio
at Baseline
CK Ratio 0–1 CK Ratio >1–2 CK Ratio >2–5 CK Ratio >5
Total population
Death 258/4,814 (5%) 97/1,546 (6%) 111/1,985 (6%) 279/3,380 (8%)
(Re)MI 286/4,747 (6%) 144/1,514 (10%) 161/1,946 (8%) 223/3,247 (7%)
Death or (re)MI 478/4,790 (10%) 218/1,541 (14%) 242/1,977 (12%) 442/3,359 (13%)
ST-elevation
Death 33/539 (6%) 19/351 (8%) 35/721 (5%) 166/2,365 (7%)
(Re)MI 37/526 (7%) 28/342 (8%) 50/705 (7%) 151/2,286 (7%)
Death or (re)MI 61/536 (11%) 44/351 (13%) 76/719 (11%) 284/2,248 (12%)
Non–ST-elevation
Death 225/4,275 (5%) 78/1,195 (7%) 76/1,264 (6%) 113/1,015 (11%)
(Re)MI 249/4,221 (6%) 116/1,172 (10%) 111/1,241 (9%) 72/961 (7%)
Death or (re)MI 417/4,254 (10%) 174/1,190 (15%) 166/1,258 (13%) 158/1,011 (16%)
Values listed indicate the number of events/number of patients (percentage).
CK  creatine kinase; MI  myocardial infarction.
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imal CK elevations. These trends were rather flat in the
ST-segment elevation cohort. In comparison with the
ST-elevation cohort, patients without ST-segment eleva-
tion and elevated CK levels had a slightly higher incidence
of (re)MI. As shown in Figure 3, (re)infarctions occurred
mostly during the first two weeks after index admission and
slightly but significantly earlier in patients with no ST-
segment elevation.
Figures 4 and 5 show the relation between peak CK levels
and the probability of cardiac events, after adjusting for the
baseline predictors of mortality or the combined end point.
In the total patient population, highly significant correla-
tions were observed between the continuous measure of CK
ratio and mortality (chi-square 65.49, p  0.0001) and
death or (re)MI (chi-square 51.00, p  0.0001), and
nonsignificant interactions were found with the ST-
segment strata (Fig. 4A and 4B). The slope of the hazard
curve for the relation between CK ratio and both end points
tended to be steeper for non–ST-segment elevation, and for
any given CK ratio the risk was higher in patients without
ST-segment elevation (Fig. 4C and 4D). Also, no signifi-
cant interaction with ST-segment strata was observed in the
categorical analysis (overall chi-square 63.04 for death and
55.48 for death or (re)MI, both p  0.0001). The adjusted
OR for death in the total population showed an increase in
the odds of mortality of 26% for a CK ratio as little as 1
to 2, increasing to 131% for CK ratios 5 (Fig. 5A). The
OR for death or (re)MI showed a 59% increase already
existing for a CK ratio 1 to 2 (Fig. 5B).
DISCUSSION
The definition of an MI has been recently revised by the
Joint Ad Hoc Committee of the European Society of
Cardiology and the American College of Cardiology (14),
and it is no longer based on the classical dichotomous
partition between normal and abnormal levels of traditional
cardiac enzymes. The revised definition now recognizes that
any elevation in the biochemical markers of myocardial
necrosis should be labeled as an MI, primarily because this
elevation is associated with a worsened prognosis and a
continuous relation starting from minimal myocardial dam-
age up to large infarcts. The new definition emanated in
large part from two recent sources: the large experience of
studies of non–ST-segment elevation ACS (mostly charac-
terized by undetectable or modest cell damage, as in the case
of the non–ST-segment elevation cohort of the present
study), and the recent availability of more sensitive and
specific biochemical markers of myocardial necrosis, such as
CK-MB mass and the troponins. The large population of
patients enrolled in trials of ACS has encouraged the
development of multivariable prognostic models based on
clinical, ECG and biochemical data (1,11,13,15,16), and
has refined the definition of the independent prognostic
value of markers of acute myocardial damage (11,13,17–22).
The prognostic impact of CK elevations in patients with
and without ST-segment elevation. Taking advantage of
the GUSTO-IIb database, the present study sought to
determine the relation between CK elevations and cardiac
Figure 3. Time course of (re)myocardial infarction (MI) after the index hospital admission in the ST-segment elevation and non–ST-segment elevation
cohorts.
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events at follow-up and to compare the cohorts with and
without ST-segment elevation on the admission ECG. This
distinction between ST-segment elevation and non–ST-
segment elevation presentations, beside having immediate
therapeutic implications, implies important differences in
terms of severity of coronary artery disease, prior cardiovas-
cular events and long-term prognosis, all of which are worse
in patients without ST-segment elevation (1,13). We found
that patients in both ST-segment strata with higher risk
characteristics (such as older age, prior cardiac events or
heart failure) develop smaller enzyme elevations. This factor
must be taken into account when looking at the unadjusted
relation between CK ratio and event rates as the negative
impact of CK elevations may be partially obscured by the
high-risk characteristics of patients with lower enzyme
levels.
Adjustment for the significant prognostic predictors re-
vealed a highly significant correlation between CK levels
and cardiac events, without significant interactions in the
ST-segment strata. The higher risk characteristics of the
non–ST-segment elevation cohort were reflected by higher
event rates associated with any CK level. An explanation for
why those with a longer history of coronary disease develop
lesser enzyme elevations during an acute ischemic episode
remains to be established. These patients may have a more
developed collateral circulation or perhaps myocardial pre-
conditioning. Reduced muscle mass might also explain
smaller enzyme release in the elderly as well as in women.
According to the present study, the risk of (re)MI is
maximal in the first few days or weeks after an ACS and
appears to increase with even minimal CK elevations
(particularly in the non–ST-segment elevation cohort),
whereas the mortality risk increases more gradually, at least
within the medium-term follow-up of the present study.
Patients without ST-elevation reveal greater instability, as
shown by a slightly higher and earlier incidence of (re)MI in
comparison with those with ST-segment elevations. Previ-
ous studies have indicated that patients with positive cardiac
markers on admission have an increased risk of (re)MI
(21–23). In the multivariate model of the Platelet glyco-
protein IIb/IIIa in Unstable angina: Receptor Suppression
Using Integrilin Therapy (PURSUIT) study, CK-MB ele-
vation was second only to old age in predicting the com-
posite end point of death or (re)MI at 30 days. When
Figure 4. Curves of the predicted probabilities averaged across all patients and adjusted for previously determined baseline covariates. Curves show the
relationships between creatine kinase (CK) ratio and adjusted probability of death or death and (re)myocardial infarction (MI) at six months. A and B refer
to the entire study population, which is split according to ST-segment presentation on the admission electrocardiogram (ECG) in C and D. No statistically
significant interaction with ECG strata was observed after correcting for the significant prognostic predictors.
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predicting the risk of death only, CK-MB ranked after age,
tachycardia, hypotension, ST-depression, and rales (16).
As hypothesized for elevated troponin levels, minimal
enzyme elevations in patients with ACS may result from
distal embolization of platelet and fibrin thrombi, emanat-
ing from an unstable coronary plaque (24,25), which may
take months to stabilize fully after the index episode (26,27),
and therefore identify patients at higher risk of (re)MI.
Conversely, a large amount of myocardial necrosis or a
history of repeated smaller infarcts puts the patient at high
risk of death in the short-term period. These findings are
consistent with those of smaller studies evaluating the risk of
CK rises not exceeding the upper normal limit or that of
CK-MB elevations with normal CK levels in patients with
suspected acute MI (27,28). As in the present study,
minimally elevated enzyme levels have been associated with
severe medical problems (cardiac or respiratory failure) in
which case these levels predicted a higher risk of death (29).
Study limitations. The use of CK for detecting myocardial
damage, which has largely been replaced by more sensitive
biochemical markers (CK-MB and troponins), may be
considered as a limitation of the present study. However,
when assessed in patients with recent, typical ischemic
symptoms and ECG signs of acute myocardial ischemia
(such as those enrolled in the GUSTO-IIb trial), the
prognostic value of CK elevations found in the present study
is entirely consistent with the data derived from the above-
mentioned smaller studies with CK-MB and troponins.
The higher sensitivity of these latter markers might have
resulted in an even steeper slope of the relation between
minor myocardial damage and cardiac events. The relation-
ship between peak CK or CK-MB levels and outcome
might be less evident in patients with ST-elevation infarc-
tion achieving early reperfusion by either pharmacological or
mechanical therapy. In fact, when reperfusion therapy is
effective, cardiac enzyme levels tend to peak higher, due to
a more rapid washout from the reperfused myocardium
(30,31), though not implying worse prognosis. In the
present study, 65% of the patients presenting with ST-
segment elevation underwent fibrinolytic therapy (13), and
an additional 14% underwent primary angioplasty (32);
however, an objective distinction between those achieving
and those not achieving reperfusion was not made, thus
precluding this important analysis.
Clinical implications. The most important clinical impli-
cation of our findings is that, for patients with an ACS, any
enzyme elevation must be considered a predictor of worse
outcome at follow-up, irrespective of the ECG presenta-
tion. Being aware of this increased risk is particularly
important in the light of recent trials showing that anti-
thrombotic therapies (such as the low-molecular-weight
heparins [33] and glycoprotein IIb/IIIa receptor blockers
[34]) and revascularization procedures [35] may be partic-
ularly effective in reducing the risk of cardiac events in
patients with elevated biochemical markers. Results of the
present study support, across the entire spectrum of the
ACS, the revised definition of MI as a continuum of risk
whose gradient is defined by the amount of myocardial
damage (14). The prevention or the reduction of the
amount of cell damage should be regarded as one of the
main therapeutic goals in patients with ACS.
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